Verastem (VSTM) said Sunday that results from partner GenFleet Therapeutics' phase 1/2 study in China of GFH375 in patients with KRAS G12D mutant advanced pancreatic ductal adenocarcinoma did not meet the median overall survival at data cutoff.

Among 59 heavily pre-treated patients, 40.7% achieved overall response rate at the 600 milligram daily dose, 91.5% experienced tumor reduction, and the disease control rate was 96.7%, the company said.

The safety profile was consistent with previous findings indicating manageable tolerability with a 4% discontinuation rate due to adverse events, it said.

Verastem shares were down 11% in recent Monday trading.

Price: 8.24, Change: -0.98, Percent Change: -10.63